Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore.
University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Aging (Albany NY). 2021 Oct 15;13(19):22666-22689. doi: 10.18632/aging.203598.
Previous meta-analyses examining the continuum of Alzheimer's disease (AD) concluded significantly decreased peripheral brain-derived neurotrophic factor (BDNF) in AD. However, across different meta-analyses, there remain inconsistent findings on peripheral BDNF levels in individuals with mild cognitive impairment (MCI). This issue has been attributed to the highly heterogenous clinical and laboratory factors. Thus, BDNF's level, discriminative accuracy for identifying all-cause MCI and its subtypes, and its associations with other biomarkers and neurocognitive domains, remain largely unknown.
To address this heterogeneity, we compared a healthy control cohort (n=56, 45 female) to an MCI cohort (n=40, 28 female), to determine whether plasma BDNF, hs-CRP, and DHEA-S can differentiate healthy from MCI individuals, including two MCI subtypes (amnestic [aMCI] and non-amnestic [non-aMCI]). The associations between BDNF with other biomarkers and neurocognitive tests were examined. Adults with cerebral palsy were included as sensitivity analyses.
Compared to healthy controls, BDNF was significantly higher in all-cause MCI, aMCI, and non-aMCI. Furthermore, BDNF had good (AUC=0.84, 95% CI=0.74 to 0.95, p<0.001) and excellent discriminative accuracies (AUC=0.92, 95% CI=0.84 to 1.00, p<0.001) for all-cause MCI and non-amnestic MCI, respectively. BDNF was significantly and positively associated with plasma hs-CRP (β=0.26, 95% CI=0.02 to 0.50, p=0.038), despite attenuated association upon controlling for BMI (β=0.15, 95% CI=-0.08 to 0.38, p=0.186). Multiple inverse associations between BDNF and detailed neurocognitive tests were also detected.
These findings suggest BDNF is increased as a compensatory mechanism in preclinical dementia, supporting the neurotrophic and partially the inflammatory hypotheses of cognitive impairment.
之前对阿尔茨海默病(AD)连续体的荟萃分析得出结论,AD 患者外周血脑源性神经营养因子(BDNF)显著降低。然而,在不同的荟萃分析中,轻度认知障碍(MCI)患者外周血 BDNF 水平的结果仍不一致。这一问题归因于高度异质的临床和实验室因素。因此,BDNF 水平、其对识别所有原因的 MCI 及其亚型的判别准确性,以及与其他生物标志物和神经认知领域的关联,在很大程度上仍然未知。
为了解决这种异质性,我们将健康对照组(n=56,45 名女性)与 MCI 组(n=40,28 名女性)进行比较,以确定血浆 BDNF、hs-CRP 和 DHEA-S 是否可以区分健康个体和 MCI 个体,包括两种 MCI 亚型(遗忘型 [aMCI]和非遗忘型 [非-aMCI])。还检查了 BDNF 与其他生物标志物和神经认知测试之间的关联。脑瘫患者也被纳入作为敏感性分析。
与健康对照组相比,所有原因的 MCI、aMCI 和非-aMCI 患者的 BDNF 水平均显著升高。此外,BDNF 对所有原因的 MCI 和非遗忘型 MCI 均具有良好的(AUC=0.84,95%CI=0.74 至 0.95,p<0.001)和优秀的判别准确性(AUC=0.92,95%CI=0.84 至 1.00,p<0.001)。BDNF 与血浆 hs-CRP 呈显著正相关(β=0.26,95%CI=0.02 至 0.50,p=0.038),尽管在控制 BMI 后,这种关联减弱(β=0.15,95%CI=-0.08 至 0.38,p=0.186)。BDNF 与详细神经认知测试之间还存在多种负相关。
这些发现表明,BDNF 作为一种代偿机制在临床前痴呆中增加,支持了神经营养和部分炎症假说对认知障碍的解释。